Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society

Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is curre...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Hyemi Kwon [verfasserIn] Eun Roh [verfasserIn] Chang Ho Ahn [verfasserIn] Hee Kyung Kim [verfasserIn] Cheol Ryong Ku [verfasserIn] Kyong Yeun Jung [verfasserIn] Ju Hee Lee [verfasserIn] Eun Heui Kim [verfasserIn] Sunghwan Suh [verfasserIn] Sangmo Hong [verfasserIn] Jeonghoon Ha [verfasserIn] Jun Sung Moon [verfasserIn] Jin Hwa Kim [verfasserIn] Mi-kyung Kim [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch ; Koreanisch

Erschienen:	2022

Schlagwörter:	adrenal glands pituitary gland thyroid gland immune checkpoint inhibitors drug-related side effects and adverse reactions endocrine system diseases

Übergeordnetes Werk:	In: Endocrinology and Metabolism - Korean Endocrine Society, 2016, 37(2022), 6, Seite 839-850
Übergeordnetes Werk:	volume:37 ; year:2022 ; number:6 ; pages:839-850

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.3803/EnM.2022.1627

Katalog-ID:	DOAJ082889783

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ082889783
003	DE-627
005	20230311004913.0
007	cr uuu---uuuuu
008	230311s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3803/EnM.2022.1627 \|2 doi
035			\|a (DE-627)DOAJ082889783
035			\|a (DE-599)DOAJ2fb0bfc93d6c4f40990412e830ec2ee3
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng \|a kor
050		0	\|a RC648-665
100	0		\|a Hyemi Kwon \|e verfasserin \|4 aut
245	1	0	\|a Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs.
650		4	\|a adrenal glands
650		4	\|a pituitary gland
650		4	\|a thyroid gland
650		4	\|a immune checkpoint inhibitors
650		4	\|a drug-related side effects and adverse reactions
650		4	\|a endocrine system diseases
653		0	\|a Diseases of the endocrine glands. Clinical endocrinology
700	0		\|a Eun Roh \|e verfasserin \|4 aut
700	0		\|a Chang Ho Ahn \|e verfasserin \|4 aut
700	0		\|a Hee Kyung Kim \|e verfasserin \|4 aut
700	0		\|a Cheol Ryong Ku \|e verfasserin \|4 aut
700	0		\|a Kyong Yeun Jung \|e verfasserin \|4 aut
700	0		\|a Ju Hee Lee \|e verfasserin \|4 aut
700	0		\|a Eun Heui Kim \|e verfasserin \|4 aut
700	0		\|a Sunghwan Suh \|e verfasserin \|4 aut
700	0		\|a Sangmo Hong \|e verfasserin \|4 aut
700	0		\|a Jeonghoon Ha \|e verfasserin \|4 aut
700	0		\|a Jun Sung Moon \|e verfasserin \|4 aut
700	0		\|a Jin Hwa Kim \|e verfasserin \|4 aut
700	0		\|a Mi-kyung Kim \|e verfasserin \|4 aut
773	0	8	\|i In \|t Endocrinology and Metabolism \|d Korean Endocrine Society, 2016 \|g 37(2022), 6, Seite 839-850 \|w (DE-627)810542803 \|w (DE-600)2802452-7 \|x 20935978 \|7 nnns
773	1	8	\|g volume:37 \|g year:2022 \|g number:6 \|g pages:839-850
856	4	0	\|u https://doi.org/10.3803/EnM.2022.1627 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/2fb0bfc93d6c4f40990412e830ec2ee3 \|z kostenfrei
856	4	0	\|u http://www.e-enm.org/upload/pdf/enm-2022-1627.pdf \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2093-596X \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2093-5978 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 37 \|j 2022 \|e 6 \|h 839-850

Indexfelder

author_variant	h k hk e r er c h a cha h k k hkk c r k crk k y j kyj j h l jhl e h k ehk s s ss s h sh j h jh j s m jsm j h k jhk m k k mkk
matchkey_str	article:20935978:2022----::muehcpitniiosnedcieiodraoiinttmnfo
hierarchy_sort_str	2022
callnumber-subject-code	RC
publishDate	2022
allfields	10.3803/EnM.2022.1627 doi (DE-627)DOAJ082889783 (DE-599)DOAJ2fb0bfc93d6c4f40990412e830ec2ee3 DE-627 ger DE-627 rakwb eng kor RC648-665 Hyemi Kwon verfasserin aut Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs. adrenal glands pituitary gland thyroid gland immune checkpoint inhibitors drug-related side effects and adverse reactions endocrine system diseases Diseases of the endocrine glands. Clinical endocrinology Eun Roh verfasserin aut Chang Ho Ahn verfasserin aut Hee Kyung Kim verfasserin aut Cheol Ryong Ku verfasserin aut Kyong Yeun Jung verfasserin aut Ju Hee Lee verfasserin aut Eun Heui Kim verfasserin aut Sunghwan Suh verfasserin aut Sangmo Hong verfasserin aut Jeonghoon Ha verfasserin aut Jun Sung Moon verfasserin aut Jin Hwa Kim verfasserin aut Mi-kyung Kim verfasserin aut In Endocrinology and Metabolism Korean Endocrine Society, 2016 37(2022), 6, Seite 839-850 (DE-627)810542803 (DE-600)2802452-7 20935978 nnns volume:37 year:2022 number:6 pages:839-850 https://doi.org/10.3803/EnM.2022.1627 kostenfrei https://doaj.org/article/2fb0bfc93d6c4f40990412e830ec2ee3 kostenfrei http://www.e-enm.org/upload/pdf/enm-2022-1627.pdf kostenfrei https://doaj.org/toc/2093-596X Journal toc kostenfrei https://doaj.org/toc/2093-5978 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2022 6 839-850
spelling	10.3803/EnM.2022.1627 doi (DE-627)DOAJ082889783 (DE-599)DOAJ2fb0bfc93d6c4f40990412e830ec2ee3 DE-627 ger DE-627 rakwb eng kor RC648-665 Hyemi Kwon verfasserin aut Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs. adrenal glands pituitary gland thyroid gland immune checkpoint inhibitors drug-related side effects and adverse reactions endocrine system diseases Diseases of the endocrine glands. Clinical endocrinology Eun Roh verfasserin aut Chang Ho Ahn verfasserin aut Hee Kyung Kim verfasserin aut Cheol Ryong Ku verfasserin aut Kyong Yeun Jung verfasserin aut Ju Hee Lee verfasserin aut Eun Heui Kim verfasserin aut Sunghwan Suh verfasserin aut Sangmo Hong verfasserin aut Jeonghoon Ha verfasserin aut Jun Sung Moon verfasserin aut Jin Hwa Kim verfasserin aut Mi-kyung Kim verfasserin aut In Endocrinology and Metabolism Korean Endocrine Society, 2016 37(2022), 6, Seite 839-850 (DE-627)810542803 (DE-600)2802452-7 20935978 nnns volume:37 year:2022 number:6 pages:839-850 https://doi.org/10.3803/EnM.2022.1627 kostenfrei https://doaj.org/article/2fb0bfc93d6c4f40990412e830ec2ee3 kostenfrei http://www.e-enm.org/upload/pdf/enm-2022-1627.pdf kostenfrei https://doaj.org/toc/2093-596X Journal toc kostenfrei https://doaj.org/toc/2093-5978 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2022 6 839-850
allfields_unstemmed	10.3803/EnM.2022.1627 doi (DE-627)DOAJ082889783 (DE-599)DOAJ2fb0bfc93d6c4f40990412e830ec2ee3 DE-627 ger DE-627 rakwb eng kor RC648-665 Hyemi Kwon verfasserin aut Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs. adrenal glands pituitary gland thyroid gland immune checkpoint inhibitors drug-related side effects and adverse reactions endocrine system diseases Diseases of the endocrine glands. Clinical endocrinology Eun Roh verfasserin aut Chang Ho Ahn verfasserin aut Hee Kyung Kim verfasserin aut Cheol Ryong Ku verfasserin aut Kyong Yeun Jung verfasserin aut Ju Hee Lee verfasserin aut Eun Heui Kim verfasserin aut Sunghwan Suh verfasserin aut Sangmo Hong verfasserin aut Jeonghoon Ha verfasserin aut Jun Sung Moon verfasserin aut Jin Hwa Kim verfasserin aut Mi-kyung Kim verfasserin aut In Endocrinology and Metabolism Korean Endocrine Society, 2016 37(2022), 6, Seite 839-850 (DE-627)810542803 (DE-600)2802452-7 20935978 nnns volume:37 year:2022 number:6 pages:839-850 https://doi.org/10.3803/EnM.2022.1627 kostenfrei https://doaj.org/article/2fb0bfc93d6c4f40990412e830ec2ee3 kostenfrei http://www.e-enm.org/upload/pdf/enm-2022-1627.pdf kostenfrei https://doaj.org/toc/2093-596X Journal toc kostenfrei https://doaj.org/toc/2093-5978 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2022 6 839-850
allfieldsGer	10.3803/EnM.2022.1627 doi (DE-627)DOAJ082889783 (DE-599)DOAJ2fb0bfc93d6c4f40990412e830ec2ee3 DE-627 ger DE-627 rakwb eng kor RC648-665 Hyemi Kwon verfasserin aut Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs. adrenal glands pituitary gland thyroid gland immune checkpoint inhibitors drug-related side effects and adverse reactions endocrine system diseases Diseases of the endocrine glands. Clinical endocrinology Eun Roh verfasserin aut Chang Ho Ahn verfasserin aut Hee Kyung Kim verfasserin aut Cheol Ryong Ku verfasserin aut Kyong Yeun Jung verfasserin aut Ju Hee Lee verfasserin aut Eun Heui Kim verfasserin aut Sunghwan Suh verfasserin aut Sangmo Hong verfasserin aut Jeonghoon Ha verfasserin aut Jun Sung Moon verfasserin aut Jin Hwa Kim verfasserin aut Mi-kyung Kim verfasserin aut In Endocrinology and Metabolism Korean Endocrine Society, 2016 37(2022), 6, Seite 839-850 (DE-627)810542803 (DE-600)2802452-7 20935978 nnns volume:37 year:2022 number:6 pages:839-850 https://doi.org/10.3803/EnM.2022.1627 kostenfrei https://doaj.org/article/2fb0bfc93d6c4f40990412e830ec2ee3 kostenfrei http://www.e-enm.org/upload/pdf/enm-2022-1627.pdf kostenfrei https://doaj.org/toc/2093-596X Journal toc kostenfrei https://doaj.org/toc/2093-5978 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2022 6 839-850
allfieldsSound	10.3803/EnM.2022.1627 doi (DE-627)DOAJ082889783 (DE-599)DOAJ2fb0bfc93d6c4f40990412e830ec2ee3 DE-627 ger DE-627 rakwb eng kor RC648-665 Hyemi Kwon verfasserin aut Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs. adrenal glands pituitary gland thyroid gland immune checkpoint inhibitors drug-related side effects and adverse reactions endocrine system diseases Diseases of the endocrine glands. Clinical endocrinology Eun Roh verfasserin aut Chang Ho Ahn verfasserin aut Hee Kyung Kim verfasserin aut Cheol Ryong Ku verfasserin aut Kyong Yeun Jung verfasserin aut Ju Hee Lee verfasserin aut Eun Heui Kim verfasserin aut Sunghwan Suh verfasserin aut Sangmo Hong verfasserin aut Jeonghoon Ha verfasserin aut Jun Sung Moon verfasserin aut Jin Hwa Kim verfasserin aut Mi-kyung Kim verfasserin aut In Endocrinology and Metabolism Korean Endocrine Society, 2016 37(2022), 6, Seite 839-850 (DE-627)810542803 (DE-600)2802452-7 20935978 nnns volume:37 year:2022 number:6 pages:839-850 https://doi.org/10.3803/EnM.2022.1627 kostenfrei https://doaj.org/article/2fb0bfc93d6c4f40990412e830ec2ee3 kostenfrei http://www.e-enm.org/upload/pdf/enm-2022-1627.pdf kostenfrei https://doaj.org/toc/2093-596X Journal toc kostenfrei https://doaj.org/toc/2093-5978 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2022 6 839-850
language	English Korean
source	In Endocrinology and Metabolism 37(2022), 6, Seite 839-850 volume:37 year:2022 number:6 pages:839-850
sourceStr	In Endocrinology and Metabolism 37(2022), 6, Seite 839-850 volume:37 year:2022 number:6 pages:839-850
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	adrenal glands pituitary gland thyroid gland immune checkpoint inhibitors drug-related side effects and adverse reactions endocrine system diseases Diseases of the endocrine glands. Clinical endocrinology
isfreeaccess_bool	true
container_title	Endocrinology and Metabolism
authorswithroles_txt_mv	Hyemi Kwon @@aut@@ Eun Roh @@aut@@ Chang Ho Ahn @@aut@@ Hee Kyung Kim @@aut@@ Cheol Ryong Ku @@aut@@ Kyong Yeun Jung @@aut@@ Ju Hee Lee @@aut@@ Eun Heui Kim @@aut@@ Sunghwan Suh @@aut@@ Sangmo Hong @@aut@@ Jeonghoon Ha @@aut@@ Jun Sung Moon @@aut@@ Jin Hwa Kim @@aut@@ Mi-kyung Kim @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	810542803
id	DOAJ082889783
language_de	englisch koreanisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ082889783</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230311004913.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3803/EnM.2022.1627</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ082889783</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ2fb0bfc93d6c4f40990412e830ec2ee3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">kor</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC648-665</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Hyemi Kwon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">adrenal glands</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pituitary gland</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">thyroid gland</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">drug-related side effects and adverse reactions</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">endocrine system diseases</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the endocrine glands. Clinical endocrinology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eun Roh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chang Ho Ahn</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hee Kyung Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cheol Ryong Ku</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kyong Yeun Jung</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ju Hee Lee</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eun Heui Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sunghwan Suh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sangmo Hong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jeonghoon Ha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jun Sung Moon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jin Hwa Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mi-kyung Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Endocrinology and Metabolism</subfield><subfield code="d">Korean Endocrine Society, 2016</subfield><subfield code="g">37(2022), 6, Seite 839-850</subfield><subfield code="w">(DE-627)810542803</subfield><subfield code="w">(DE-600)2802452-7</subfield><subfield code="x">20935978</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:37</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:839-850</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3803/EnM.2022.1627</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/2fb0bfc93d6c4f40990412e830ec2ee3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.e-enm.org/upload/pdf/enm-2022-1627.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2093-596X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2093-5978</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">37</subfield><subfield code="j">2022</subfield><subfield code="e">6</subfield><subfield code="h">839-850</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Hyemi Kwon
spellingShingle	Hyemi Kwon misc RC648-665 misc adrenal glands misc pituitary gland misc thyroid gland misc immune checkpoint inhibitors misc drug-related side effects and adverse reactions misc endocrine system diseases misc Diseases of the endocrine glands. Clinical endocrinology Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
authorStr	Hyemi Kwon
ppnlink_with_tag_str_mv	@@773@@(DE-627)810542803
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC648-665
illustrated	Not Illustrated
issn	20935978
topic_title	RC648-665 Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society adrenal glands pituitary gland thyroid gland immune checkpoint inhibitors drug-related side effects and adverse reactions endocrine system diseases
topic	misc RC648-665 misc adrenal glands misc pituitary gland misc thyroid gland misc immune checkpoint inhibitors misc drug-related side effects and adverse reactions misc endocrine system diseases misc Diseases of the endocrine glands. Clinical endocrinology
topic_unstemmed	misc RC648-665 misc adrenal glands misc pituitary gland misc thyroid gland misc immune checkpoint inhibitors misc drug-related side effects and adverse reactions misc endocrine system diseases misc Diseases of the endocrine glands. Clinical endocrinology
topic_browse	misc RC648-665 misc adrenal glands misc pituitary gland misc thyroid gland misc immune checkpoint inhibitors misc drug-related side effects and adverse reactions misc endocrine system diseases misc Diseases of the endocrine glands. Clinical endocrinology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Endocrinology and Metabolism
hierarchy_parent_id	810542803
hierarchy_top_title	Endocrinology and Metabolism
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)810542803 (DE-600)2802452-7
title	Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
ctrlnum	(DE-627)DOAJ082889783 (DE-599)DOAJ2fb0bfc93d6c4f40990412e830ec2ee3
title_full	Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
author_sort	Hyemi Kwon
journal	Endocrinology and Metabolism
journalStr	Endocrinology and Metabolism
callnumber-first-code	R
lang_code	eng kor
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
container_start_page	839
author_browse	Hyemi Kwon Eun Roh Chang Ho Ahn Hee Kyung Kim Cheol Ryong Ku Kyong Yeun Jung Ju Hee Lee Eun Heui Kim Sunghwan Suh Sangmo Hong Jeonghoon Ha Jun Sung Moon Jin Hwa Kim Mi-kyung Kim
container_volume	37
class	RC648-665
format_se	Elektronische Aufsätze
author-letter	Hyemi Kwon
doi_str_mv	10.3803/EnM.2022.1627
author2-role	verfasserin
title_sort	immune checkpoint inhibitors and endocrine disorders: a position statement from the korean endocrine society
callnumber	RC648-665
title_auth	Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
abstract	Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs.
abstractGer	Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs.
abstract_unstemmed	Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	6
title_short	Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
url	https://doi.org/10.3803/EnM.2022.1627 https://doaj.org/article/2fb0bfc93d6c4f40990412e830ec2ee3 http://www.e-enm.org/upload/pdf/enm-2022-1627.pdf https://doaj.org/toc/2093-596X https://doaj.org/toc/2093-5978
remote_bool	true
author2	Eun Roh Chang Ho Ahn Hee Kyung Kim Cheol Ryong Ku Kyong Yeun Jung Ju Hee Lee Eun Heui Kim Sunghwan Suh Sangmo Hong Jeonghoon Ha Jun Sung Moon Jin Hwa Kim Mi-kyung Kim
author2Str	Eun Roh Chang Ho Ahn Hee Kyung Kim Cheol Ryong Ku Kyong Yeun Jung Ju Hee Lee Eun Heui Kim Sunghwan Suh Sangmo Hong Jeonghoon Ha Jun Sung Moon Jin Hwa Kim Mi-kyung Kim
ppnlink	810542803
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3803/EnM.2022.1627
callnumber-a	RC648-665
up_date	2024-07-03T14:23:06.390Z
_version_	1803568112097820672
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ082889783</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230311004913.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3803/EnM.2022.1627</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ082889783</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ2fb0bfc93d6c4f40990412e830ec2ee3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">kor</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC648-665</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Hyemi Kwon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">adrenal glands</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pituitary gland</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">thyroid gland</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">drug-related side effects and adverse reactions</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">endocrine system diseases</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the endocrine glands. Clinical endocrinology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eun Roh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chang Ho Ahn</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hee Kyung Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cheol Ryong Ku</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kyong Yeun Jung</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ju Hee Lee</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eun Heui Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sunghwan Suh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sangmo Hong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jeonghoon Ha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jun Sung Moon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jin Hwa Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mi-kyung Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Endocrinology and Metabolism</subfield><subfield code="d">Korean Endocrine Society, 2016</subfield><subfield code="g">37(2022), 6, Seite 839-850</subfield><subfield code="w">(DE-627)810542803</subfield><subfield code="w">(DE-600)2802452-7</subfield><subfield code="x">20935978</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:37</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:839-850</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3803/EnM.2022.1627</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/2fb0bfc93d6c4f40990412e830ec2ee3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.e-enm.org/upload/pdf/enm-2022-1627.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2093-596X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2093-5978</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">37</subfield><subfield code="j">2022</subfield><subfield code="e">6</subfield><subfield code="h">839-850</subfield></datafield></record></collection>
score	7.401045

Nicht das Richtige dabei?

Schreiben Sie uns!

Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?